INmune Bio Secures MHRA Approval of Pediatric Investigation Plan for Ebstrocel in RDEB, Clearing Key Regulatory Hurdle
Key Insights
INmune Bio received MHRA approval of its Pediatric Investigation Plan for Ebstrocel (search), an investigational cell therapy for recessive dystrophic epidermolysis bullosa (search), in under three months following an accelerated review.
The MHRA's written alignment from a May 2026 Scientific Advice meeting validates the CMC, non-clinical, and clinical evidence packages, providing a clear roadmap toward a planned 2026 UK Conditional Marketing Authorization submission.
The agency recognized MissionEB Phase 2 data as demonstrating clinically meaningful symptomatic benefit, particularly in pain and pruritus, and indicated the data could support positioning Ebstrocel (search) as a chronic or intermittent supportive therapy for RDEB.
INmune Bio Inc. (NASDAQ: INMB) has achieved a significant regulatory milestone with the UK Medicines & Healthcare products Regulatory Agency (MHRA) approving the Pediatric Investigation Plan (PIP) for Ebstrocel (search), the company's investigational cell therapy for recessive dystrophic epidermolysis bullosa (search) (RDEB). The approval, announced June 25, 2026, arrived in under three months following an accelerated review requested by the company based on the critical unmet need in this devastating pediatric disease.
The PIP approval represents the first required stage toward a Marketing Authorization Application (MAA) submission in the United Kingdom and keeps the company on track for an MAA filing in 2026 and a US filing for Accelerated Approval in early 2027.
"We submitted the PIP for Ebstrocel (search) expecting a ten-month review cycle, but requested an accelerated review based on the critical unmet need in RDEB," said Dr. Mark Lowdell, Chief Scientific Officer of INmune Bio. "The MHRA's turnaround in under three months represents a clear endorsement of the clinical data package."
Regulatory Alignment Across Key Domains
The PIP approval follows closely on the heels of another critical regulatory achievement. On June 23, 2026, INmune Bio announced it had received official, accepted meeting minutes from a May 12, 2026, face-to-face pre-MAA Scientific Advice meeting with the MHRA, which resulted in written alignment across all questions submitted by the company covering chemistry, manufacturing and controls (CMC), non-clinical, and clinical evidence packages.
"The minutes give us a practical roadmap to completing the MAA package for potential conditional authorization in the UK," said David Moss, Chief Executive Officer of INmune Bio.
The MHRA affirmed that INmune Bio's proprietary pooled-donor approach is acceptable, supported by the company's data-characterization package and donor-contribution controls. The agency also concurred with the company's analytical and comparability plans to transition manufacturing to commercial platforms. Regulators further agreed with the strategy to use a focused, literature-supported non-clinical safety package, supplemented by in vitro safety and pharmacology data, avoiding redundant animal testing.
Clinical Evidence and Endpoint Refinements
In its written comments on the pediatric investigation plan, the MHRA recognized MissionEB Phase 2 data as demonstrating "clinically meaningful symptomatic benefit, particularly in pain and pruritus." The agency noted that while MissionEB showed improvements in wound quality, inflammation, and granulation during treatment periods, it did not demonstrate durable wound closure or sustained reduction in total wound burden after treatment cessation.
"Nevertheless, these data could support the positioning as chronic or intermittent supportive therapy for RDEB," the MHRA stated in its feedback.
Dr. Lowdell elaborated on the company's response: "The MHRA feedback has been very valuable, constructive and highly specific. We are implementing MHRA's recommendations, including refinements to the primary and secondary endpoints, which move away from a focus on wound closure, and broadening the planned pediatric age range to 0 to 18 years."
The agency also provided guidance on statistical approaches suited to ultra-rare diseases, noting that traditional frequentist statistical analyses may be less informative in small orphan populations. The MHRA invited INmune Bio to incorporate alternative approaches, including Bayesian statistical models and qualitative patient and parent interview data describing improvements in systemic symptoms such as chronic pain, intractable itch, and sleep quality.
Disease Burden and Unmet Need
RDEB is characterized not merely as a skin condition but as a devastating systemic disease. The Ebstrocel (search) PIP submission highlighted the therapy's potential to address the most debilitating symptoms reported by the patient community: chronic wounds, intractable itch, and severe pain, which are the primary drivers of poor quality of life.
Approximately 300 children are affected by RDEB in the United Kingdom, part of a broader epidermolysis bullosa community of at least 5,000 individuals supported by DEBRA UK. The MHRA raised no objections to the clinical data or the claims presented in the submission.
Path Toward Commercialization
Ebstrocel (search) is the RDEB-specific investigational formulation derived from INmune Bio's proprietary CORDStrom (search) platform, which comprises aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. The platform leverages proprietary screening, pooling, and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines to treat complex inflammatory and autoimmune diseases.
"Securing PIP approval ahead of schedule, together with the MHRA's written alignment across our CMC, non-clinical and clinical strategy, represents a significant regulatory de-risking milestone for Ebstrocel (search) and the broader CORDStrom (search) platform," said Moss. "With these milestones achieved, we believe Ebstrocel is now positioned on a well-defined path to potential approval, bringing us closer to delivering the first systemic therapy designed to address the underlying disease burden of RDEB."
The company is now focused on final preparations for the MAA submission and completing the final commercial manufacturing steps necessary for Ebstrocel (search) authorization. INmune Bio also intends to use the MHRA feedback to inform future interactions with the European Medicines Agency and the U.S. Food and Drug Administration, with additional filings planned in late 2026 or early 2027.